SimBioSys®, a leading TechBio company pioneering the fusion of spatial biophysics with artificial intelligence (AI) and computational modeling to redefine precision medicine for cancer, has unveiled its latest innovation, TumorSight Plan. This groundbreaking clinical decision support application represents a significant advancement in surgical planning for the over 270,000 patients diagnosed annually with early-stage breast cancer in the U.S.

Surgery stands as the primary treatment for most early-stage breast cancer patients. However, the lack of precise tools for treatment planning often results in decisions favoring mastectomy over breast-conserving surgery. TumorSight Plan aims to address this gap by empowering surgeons with advanced visualization, data-driven insights, and best practices to support more effective provider-patient interactions and individualized treatment planning.

TumorSight Plan leverages the FDA-cleared TumorSight Viz, a state-of-the-art 3D visualization solution tailored for Breast Cancer MRI imaging, to provide surgeons with unparalleled clarity and precision in treatment planning. Both TumorSight Plan and Viz are now available to breast surgeons nationwide and will be showcased at the American Association of Breast Surgeon's conference in Orlando from April 11th to 13th.

Dr. Christy Teal, Director of Breast Care Center and Chief of Breast Surgery at GW Medical, hailed the significance of SimBioSys' TumorSight suite in empowering personalized decision-making in breast cancer care. "SimBioSys is leading breast surgeons and patients into an era of greater confidence in personalized decision making," remarked Dr. Teal, a respected co-author of "No Longer Radical. Understanding Mastectomies and Choosing the Breast Cancer Care That’s Right For You."

SimBioSys remains committed to expanding the TumorSight™ platform, with plans to integrate innovative tools across surgical planning, risk assessment, treatment selection, and precision dosing. This comprehensive approach embodies the promise of true precision medicine, providing holistic support throughout the cancer care journey.

Dr. Barry Rosen, CMO of SimBioSys and breast surgical oncologist, emphasized the transformative potential of TumorSight Plan in enabling more analytical patient-centric decision making. "TumorSight Plan gives the breast cancer surgeon a platform and opportunity to enable more analytical patient-centric decision making, leading to a higher percentage of women undergoing breast conservation surgery," Dr. Rosen affirmed.

With TumorSight Plan, SimBioSys heralds a new era of precision in breast cancer care, empowering surgeons to tailor treatment strategies to individual patient needs while enhancing overall outcomes and patient satisfaction.